Welcome to our dedicated page for Femasys news (Ticker: $FEMY), a resource for investors and traders seeking the latest updates and insights on Femasys stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Femasys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Femasys's position in the market.
Rhea-AI Summary
Femasys prepares to launch FemaSeed® in the U.S. amidst legal uncertainty after Alabama Supreme Court ruling. The company plans to release top-line data from a pivotal clinical trial in Q1 2024. FemaSeed offers a cost-effective and safe alternative to traditional assisted reproductive methods, aiming to revolutionize fertilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
-
Rhea-AI Summary
Femasys Inc. appoints Richard Spector as chief commercial officer to lead the commercial launch of FemaSeed, a novel solution for infertility, and FemBloc, a non-surgical permanent birth control. Mr. Spector brings 25 years of experience in leading public and private healthcare companies and will be granted 100,000 shares of Femasys common stock as an inducement for his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.25%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announced the activation of enrollment for its pivotal FemBloc trial at the University of California, Davis Medical Center. The trial aims to investigate the safety and efficacy of FemBloc, a non-surgical, permanent birth control candidate. This marks the third academic center to participate in the trial, with Dr. Mitchell Creinin as an initial advisor. The trial is designed to address the high unmet need for women seeking permanent birth control, for whom elective surgery remains the only option. Femasys is focused on creating accessible innovative options for women, with a broad portfolio of in-office, accessible solutions and late-stage clinical development for permanent birth control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
Rhea-AI Summary
Femasys Inc. announces the activation of enrollment for its pivotal FemBloc trial at the University of Utah Hospital, led by Dr. Lori Gawron, M.D. The trial is designed to investigate the safety and efficacy of FemBloc, a non-surgical permanent birth control solution. The company is focused on providing accessible solutions for women worldwide, with a broad portfolio of products in late-clinical stage development and FDA-cleared products. The involvement of University of Utah Hospital and Dr. Gawron demonstrates support for FemBloc and its potential to provide improved birth control options for women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) has activated enrollment for its pivotal FemBloc® trial at Stanford Medicine to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The trial aims to address the high unmet need for women seeking permanent birth control, for whom elective surgery currently remains the only option. Femasys is focused on creating accessible innovative options for women, exemplified by its lead product candidate, FemBloc, and its FDA-cleared product, FemaSeed®, for infertility treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) appoints Dr. James Liu, M.D., a renowned figure from a top-ranked academic gynecology program, as Chief Medical Officer. Dr. Liu's appointment comes as Femasys accelerates the commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®. With significant clinical and leadership experience, Dr. Liu is expected to support Femasys' efforts in reproductive health and product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
Rhea-AI Summary
Femasys Inc. (FEMY) completes enrollment in the LOCAL FemaSeed® pivotal clinical trial for male factor infertility, with commercial launch planned for early 2024. The company's lead product candidate FemBloc® is in late-stage clinical development for permanent birth control. FemaSeed, an FDA-cleared infertility treatment, aims to provide accessible options for women's health. The company also focuses on developing complementary diagnostic products with regulatory approvals in the U.S., Canada, and other ex-U.S. territories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
-
News
Rhea-AI Summary
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) announces a $5 million investment in Femasys, Inc. (Nasdaq:FEMY), marking an expansion of its corporate strategy to create additional shareholder value. The investment aims to utilize PharmaCyte's significant cash position and contribute to Femasys' development of innovative women's health solutions, including a non-surgical, in-office permanent birth control method.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.6%
Tags
-
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) secured a $6.85 million upfront investment from PharmaCyte Biotech, Inc. and other healthcare investors, providing a total cash runway of $23 million until the second half of 2025. This investment will support the commercialization of infertility-related products and the advancement of FemBloc, Femasys' lead product candidate for permanent birth control, to initial clinical data readout. The investment is in the form of a senior unsecured convertible note and includes warrants to purchase approximately 5.8 million shares of common stock at varying exercise prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.6%
Tags
Rhea-AI Summary
Femasys Inc. (Nasdaq: FEMY) gained 510(k) product clearance for FemaSeed, commenced patient enrollment in the FINALE trial for FemBloc, and raised $11.3 million. The company also achieved compliance with Nasdaq's minimum bid price requirement and announced financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.58%
Tags
Femasys Inc.
Nasdaq:FEMY
FEMY Rankings
FEMY Stock Data
28.44M
19.87M
7.64%
6.42%
7.88%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SUWANEE
About FEMY
our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t